ReviewJournal of clinical pathology2006
An update on molecular genetics of gastrointestinal stromal tumours.
Review in Journal of clinical pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01227746 (A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.
Who cites it
26 citing papers in PubMed, 107 citations in OpenAlex.
- Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors.Cancer research · 2026Article
- From KIT-mutated into wild-type: dedifferentiation of gastrointestinal stromal tumor in adolescent patient-a case report.Journal of gastrointestinal oncology · 2023Article
- Deep learning predicts patients outcome and mutations from digitized histology slides in gastrointestinal stromal tumor.NPJ precision oncology · 2023Article
- Review
- Prognostic Indicators for Gastrointestinal Stromal Tumors: A Review.Translational oncology · 2020Review
- Tumor-targetingHeliyon · 2018Article
- Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model.Cell cycle (Georgetown, Tex.) · 2018Article
- Metastatic Liver Disease Associated with Gastrointestinal Stromal Tumors: Controversies in Diagnostic and Therapeutic Approach.Journal of gastrointestinal cancer · 2015Review
- [Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology].Der Pathologe · 2014Review
- Gastrointestinal stromal tumor - an evolving concept.Frontiers in medicine · 2014Review
- Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.PloS one · 2014Article
- MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.British journal of cancer · 2013Article
- Low expression of cyclinH and cyclin-dependent kinase 7 can decrease the proliferation of human esophageal squamous cell carcinoma.Digestive diseases and sciences · 2013Article
- Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.Medical oncology (Northwood, London, England) · 2013Article
- C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.Medical oncology (Northwood, London, England) · 2012Article
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours.Journal of gastroenterology · 2011Article
- Article
- Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors.BMC medicine · 2010Article
- Loss of RKIP expression is associated with poor survival in GISTs.Virchows Archiv : an international journal of pathology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumours (GISTs) are the most common primary mesenchymal tumours of the gastrointestinal tract. Most of them show activating mutations of the genes coding for KIT or platelet-derived growth factor receptor alpha (PDGFRalpha), two receptor tyrosine kinases (RTKs). The RTK inhibitor Imatinib (Gleevec, Novartis, Switzerland), induces regression of the tumour. The level of response to treatment, together with other clinicopathological parameters is related to the type and site of the activating mutation, thus suggesting that these tumours should be classified according to the molecular context. This is confirmed also by the phenomenon of the resistance to treatment, which arises because of different mechanisms (second mutation, amplification, activation of other RTKs) and can be fought only by specific RTK inhibitors, that are at present under development. RTK activation involves an homogeneous transduction pathway whose components (MAPK, AKT, PI3K, mTOR and RAS) are possible targets of new molecular treatment. A new paradigm of classification integrating the classic pathological criteria with the molecular changes will permit personalised prognosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.